valproate vpa valproic acid sodium valproate valproate semisodium forms medications primarily used treat epilepsy bipolar disorder prevent migraine useful prevention seizures absence seizures partial seizures generalized given intravenously mouth tablet forms exist long shortacting common side effects valproate include nausea vomiting somnolence dry serious side effects include liver failure regular monitoring liver function tests therefore serious risks include pancreatitis increased suicide valproate known cause serious abnormalities fetuses taken contraindicated women childbearing age unless drug essential medical drug still prescribed uk potentially pregnant women use declined valproates precise mechanism action proposed mechanisms include affecting gaba levels blocking voltagegated sodium channels inhibiting histone deacetylases increasing valproic acid branched shortchain fatty acid scfa derivative valeric valproate first made came medical use world health organizations list essential available generic commonly prescribed medication united states million valproate negative ion conjugate acid valproate valproic acid vpa valproic acid fully ionized valproate physiologic ph human body valproate active form drug sodium valproate sodium salt valproic acid divalproex sodium coordination complex composed equal parts valproic acid sodium used primarily treat epilepsy bipolar disorder also used prevent migraine valproate broad spectrum anticonvulsant activity although primarily used firstline treatment seizures absence seizures myoclonic seizures secondline treatment partial seizures infantile also successfully given intravenously treat status valproate products also used treat manic mixed episodes bipolar systematic review compared efficacy valproate addon people based upon five case reports valproic acid may efficacy controlling symptoms dopamine dysregulation syndrome arise treatment parkinsons disease valproate also used prevent migraine headaches medication tested treatment aids cancer owing histonedeacetylaseinhibiting contraindications include common adverse effects serious adverse effects valproic acid black box warning hepatotoxicity pancreatitis fetal worthy mentioning adverse effects related valproic acid may dosedependent evidence valproic acid may cause premature growth plate ossification children adolescents resulting decreased valproic acid also cause mydriasis dilation evidence shows valproic acid may increase chance polycystic ovary syndrome pcos women epilepsy bipolar disorder studies shown risk pcos higher women epilepsy compared bipolar weight gain also valproate causes birth exposure pregnancy associated three times many major abnormalities usual mainly spina bifida risks related strength medication used use one fetal valproate syndrome fvs used refer effects valproate exposure however similar discussion adverse effect exposure alcohol utero fetal alcohol spectrum disorder study proposed term fetal valproate spectrum disorder fvsd valproate exposure lead wide range possible presentations influenced various factors including dosage timing exposure dysmorphic features associated vpa exposure subtle agedependent making challenging designate individuals characteristic dysmorphism especially limited expertise area presence typical facial dysmorphism suggestive condition required diagnosis change terminology fvsd would benefit individuals affected neurodevelopmental effects vpa exposure without significant malformations since experience impairments everyday functioning similar classical characteristics valproate syndrome may include facial features tend evolve age including triangleshaped forehead tall forehead bifrontal narrowing epicanthic folds medial deficiency eyebrows flat nasal bridge broad nasal root anteverted nares shallow philtrum long upper lip thin vermillion borders thick lower lip small downturned developmental delay usually associated altered physical characteristics dysmorphic features always children mothers taking valproate pregnancy risk lower maternal valproate use pregnancy increased probability autism offspring compared mothers taking valproate study found rates autism among children exposed sodium valproate birth cohort studied normal incidence autism general population estimated updated march report estimates number increased approximately boys study found children pregnant women taking valproate iq nine points lower wellmatched control group however research older children adults sodium valproate associated paroxysmal tonic upgaze childhood also known syndrome childhood fetal exposure condition resolved discontinuing valproate women intend become pregnant switch different medication possible decrease dose women become pregnant taking valproate warned causes birth defects cognitive impairment newborn especially high doses although valproate sometimes drug control seizures seizures pregnancy could worse outcomes fetus exposure valproate studies shown taking folic acid supplements reduce risk congenital neural tube use valproate migraine bipolar disorder pregnancy contraindicated european union united states medicines recommended epilepsy pregnancy unless effective treatment valproate may cause increased somnolence elderly trial valproate elderly patients dementia significantly higher portion valproate patients somnolence compared placebo approximately onehalf patients associated reduced nutritional intake weight excessive amounts valproic acid result somnolence tremor stupor respiratory depression coma metabolic acidosis general serum plasma valproic acid concentrations range mgl controlled therapy may reach mgl following acute poisoning monitoring serum level often accomplished using commercial immunoassay techniques although laboratories employ gas liquid contrast antiepileptic drugs present little favorable evidence salivary therapeutic drug monitoring salivary levels valproic acid correlate poorly serum levels partly due valproates weak acid property pka severe intoxication hemoperfusion hemofiltration effective means hastening elimination drug supportive therapy given patients experiencing overdose urine output supplemental lcarnitine indicated patients acute also high risk patients acetyllcarnitine lowers hyperammonemia less lcarnitine valproate inhibits glucuronyl transferase epoxide hydrolase highly protein bound hence may interact drugs substrates enzymes highly protein bound may also potentiate cns depressant effects given conjunction antiepileptics due potential reduced clearance antiepileptics including carbamazepine lamotrigine phenytoin phenobarbitone may also interact although mechanism action valproate fully traditionally anticonvulsant effect attributed blockade voltagegated sodium channels increased brain levels gammaaminobutyric acid gabaergic effect also believed contribute towards antimanic properties animals sodium valproate raises cerebral cerebellar levels inhibitory synaptic neurotransmitter gaba possibly inhibiting gaba degradative enzymes gaba transaminase succinatesemialdehyde dehydrogenase inhibiting reuptake gaba neuronal prevention neurotransmitterinduced hyperexcitability nerve cells via channel may also contribute also shown protect seizureinduced reduction phosphatidylinositol potential therapeutic also histonedeacetylaseinhibiting effects inhibition histone deacetylase promoting transcriptionally active chromatin structures likely presents epigenetic mechanism regulation many neuroprotective effects attributed valproic acid intermediate molecules mediating effects include vegf bdnf valproic acid found antagonist androgen progesterone receptors hence nonsteroidal antiandrogen antiprogestogen concentrations much lower therapeutic serum addition drug identified potent aromatase inhibitor suppresses estrogen actions likely involved reproductive endocrine disturbances seen valproic acid valproic acid found directly stimulate androgen biosynthesis gonads via inhibition histone deacetylases associated hyperandrogenism women increased levels high rates polycystic ovary syndrome menstrual disorders also observed women treated valproic taken mouth valproate rapidly virtually completely absorbed bloodstream substance bound plasma proteins mainly albumin protein binding saturable decreases increasing valproate concentration low albumin concentrations patients age additional use drugs aspirin well liver kidney concentrations cerebrospinal fluid breast milk blood plasma vast majority valproate metabolism occurs valproate known metabolized cytochrome enzymes also known metabolized udpglucuronosyltransferase enzymes known metabolites valproate enzymes uncharacterized enzymes include see metabolites adult patients taking valproate alone administered dose excreted urine glucuronide major pathway metabolism valproate mitochondrial beta oxidation typically accounts administered typically less administered dose eliminated oxidative less administered dose valproate excreted unchanged ie valproate small amount excreted via elimination halflife hours decrease hours combined enzyme valproic acid branched shortchain fatty acid derivative valeric valproic acid first synthesized beverly burton analogue valeric acid found naturally valproic acid carboxylic acid clear liquid room temperature many decades use laboratories metabolically inert solvent organic compounds french researcher pierre eymard serendipitously discovered anticonvulsant properties valproic acid using vehicle number compounds screened antiseizure activity found prevented pentylenetetrazolinduced convulsions laboratory approved antiepileptic drug france become widely prescribed antiepileptic drug valproic acid also used migraine prophylaxis bipolar valproate available generic pharmaceutical company abbott paid billion fines us federal state governments illegal promotion offlabel uses depakote including sedation elderly nursing home studies suggested valproate may reopen critical period learning absolute pitch possibly skills valproate exists two main molecular variants sodium valproate valproic acid without sodium often implied simply valproate mixture two termed semisodium valproate unclear whether difference efficacy variants except fact mass sodium valproate needed valproic acid without sodium compensate sodium branded products include formulations much europe dépakine depakine chrono tablets equivalent epilim epilim chrono depalept depalept chrono extended release tablets equivalent epilim epilim chrono manufactured distributed sanofiaventis systematic review literature identified one study valproate evaluated treatment seizures infants aged months randomized control trial valproate alone found show poorer outcomes infants valproate plus levetiracetam terms reduction seizures freedom seizures daily living ability quality life cognitive httpsenwikipediaorgwikivalproate